lerodalcibep (Lerochol)

From Aaushi
Jump to navigation Jump to search
[1]

Indications

* will enter the market in the spring of 2026

Dosage

  • monthly injection

Mechanism of action

More general terms

References

  1. ↑ Lou N Third-Generation PCSK9 Inhibitor Approved for High Cholesterol. Lerodalcibep, delivered as a monthly shot, will enter the market in the spring of 2026. MedPage Today. December 16, 2025 https://www.medpagetoday.com/cardiology/dyslipidemia/119050
Retrieved from "https://aaushi.info/w/index.php?title=A59455&oldid=1283150"